# Esprit BTK Post-Approval Study

Study · id `cardio:ct-nct06656364` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06656364](<https://clinicaltrials.gov/study/NCT06656364>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06656364

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 200 participants.

## Technical summary

Registry record NCT06656364. Allocation not applicable; no masking; primary purpose treatment. Start 2024-10-21 (actual); primary completion 2027-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT06656364, source copy `cardio:ctgov-nct06656364-2026-03-25`, retrieved 2026-10-31)
- Started: 2024-10-21 (actual) (ClinicalTrials.gov record NCT06656364, source copy `cardio:ctgov-nct06656364-2026-03-25`, retrieved 2026-10-31)
- Primary completion: 2027-04-30 (anticipated) (ClinicalTrials.gov record NCT06656364, source copy `cardio:ctgov-nct06656364-2026-03-25`, retrieved 2026-10-31)
- Completion: 2029-05-30 (anticipated) (ClinicalTrials.gov record NCT06656364, source copy `cardio:ctgov-nct06656364-2026-03-25`, retrieved 2026-10-31)
- Countries: United States; Hong Kong SAR China; New Zealand; United Arab Emirates (ClinicalTrials.gov record NCT06656364, source copy `cardio:ctgov-nct06656364-2026-03-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06656364-2026-03-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: Esprit BTK Post-Approval Study
- Acronym: EspritBTKPAS
- Condition: Chronic Limb-Threatening Ischemia
- Intervention (Device): Esprit BTK System
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: 58ac242407d49a8bbc93c3e73dbd0a4bfeac783c0ced535e987d7c67122beaea
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
